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USE OF AN AUTOMATED PROCESS TO SCAN AND INTERPRET MANUALLY-CODED DATA FORMS IN PHARMACOECONOMICS RESEARCH
OBJECTIVE:
The reliability of a computer program to automatically scan and interpret data from manually-coded, data-collection forms was evaluated in a resource-utilization study of patients undergoing total knee-replacement surgery and receiving low molecular-weight heparin therapy to prevent deep vein thrombosis. METHODS: Detailed in-patient data was extracted by technicians via manual chart review and recorded on 13-page forms. To expedite the analysis, Teleform 6.2 was used to design the data-collection form and later, to automatically scan and interpret each form returned. RESULTS: The reliability of this technology was evaluated for the first 100 eligible-patient forms received. Of all field entries, Teleform automatically processed 89.9% without an operator verification prompt. The remaining ambiguous fields were viewed and edited on screen by an operator. Data for each completed form was then forwarded to an output data set. The output data set records were compared against screen images of the original data forms to determine the reliability of this process. An average of 183 field entries was recorded for each patient and scanned by Teleform. 99.0% of the fields in the output data set matched completely with the handwritten field entries on the original forms. This reliability varied slightly with the type of field analyzed. Check box, date, numeric, and alphanumeric fields had reliability scores of 100.0%, 99.8%, 99.6% and 96.5%, respectively. CONCLUSION: This program shows promise for organizations that routinely collect information on hard-copy forms, though the required learning curve and cost hampers its value for the occasional user or for small projects.
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THE 'NICE' APPROACH TO PHARMACOECONOMICS: AN ECONOMICS PERSPECTIVE Birch S, Gafni A McMaster University, Hamilton, ON, Canada
OBJECTIVE:
The National Institute for Clinical Excellence (NICE) is a UK government-funded body that responds to requests for guidance from the Department for Health on the use of selected new and established technologies in the NHS in England and Wales. In March 2001 NICE published its "guidance to manufacturers" for these submissions, essentially economic evaluation guidelines for publicly-funded health-care services including, but not restricted to, pharmaceuticals. This presentation analyzes the extent to which the NICE guidelines use economics to contribute to the goals articulated in the NICE documentation for health maximization and to remove unfairness in the availability of technologies under a fixed NHS resource constraint. METHODS: We analyze from an economics perspective the problems giving rise to the need for guidelines, the theoretical basis of the guidelines, and the implications of the guidelines for health maximization and rectifying unfair availability. RESULTS: The NICE guidelines fail to reflect important economic aspects concerned with constrained health maximization and unfair availability. The guidelines cannot be expected to lead to maximization of health gain from NHS resources and hence may fail to serve the needs of NHS decision-makers. In addition, use of the guidelines could result in continued expansion of expenditures as predicted by economic analysis. CONCLUSIONS: The guidelines aim to provide systemwide solutions, based on standardized methods, to what are essentially locally-based, non-standardized problems. Although guidelines might be helpful in dealing with matters of administrative process, the need for or ability of such an approach to accommodate the intellectual
